skip to content
18-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer Preview this item
ClosePreview this item
Checking...

18-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer

Author: Cancer Care Ontario. Lung Cancer Disease Site Group,; Cancer Care Ontario. Program in Evidence-based Care,; Cancer Care Ontario,
Publisher: Toronto, Ontario : Cancer Care Ontario, 2012.
Series: Evidence-based series (Cancer Care Ontario), no. 7-20, version 2.
Edition/Format:   eBook : Document : State or province government publication : EnglishView all editions and formats
Summary:
"Questions: What is the role of 18-Fluorodeoxyglucose (18FDG) Positron Emission Tomography (PET) in: 1. The diagnosis of solitary pulmonary nodules (SPN)? 2. The staging of primary non-small cell lung cancer (NSCLC) at initial diagnosis? 3. The staging of primary small cell lung cancer (SCLC)? Outcomes of interest include accuracy measures of imaging and the impact of PET on patient management and patient  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Electronic books
Practice Guideline
Material Type: Document, Government publication, State or province government publication, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Cancer Care Ontario. Lung Cancer Disease Site Group,; Cancer Care Ontario. Program in Evidence-based Care,; Cancer Care Ontario,
OCLC Number: 860710518
Description: 1 online resource (58 pages).
Contents: 1. Clinical practice guideline (endorsed) --
2. Systematic review --
3. Guideline development and external review --
4. Guideline summary review.
Series Title: Evidence-based series (Cancer Care Ontario), no. 7-20, version 2.
Other Titles: EBS 7-20, version 2.
Responsibility: members of the Lung Cancer Disease Site Group ; a quality initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO).
More information:

Abstract:

"Questions: What is the role of 18-Fluorodeoxyglucose (18FDG) Positron Emission Tomography (PET) in: 1. The diagnosis of solitary pulmonary nodules (SPN)? 2. The staging of primary non-small cell lung cancer (NSCLC) at initial diagnosis? 3. The staging of primary small cell lung cancer (SCLC)? Outcomes of interest include accuracy measures of imaging and the impact of PET on patient management and patient outcomes"--Page 1.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.